GAS6 and prostate cancer: Moreover, when prostate cancer cells were injected into wild-type or GAS6-null skeletal tissue, significantly greater CSCs were identified near the endosteal surfaces of GAS6 expressing tissues compared to tissues lacking GAS6 (Figure 4B–4C).